Phenoxypropazine (trade name Drazine) is an irreversible and non-selective monoamine oxidase inhibitor (MAOI) of the hydrazine family.

It was introduced as an antidepressant in 1961, but was subsequently withdrawn in 1966 due to hepatotoxicity concerns.

[1][2][3][4][5]

This drug article relating to the nervous system is a stub.

You can help Wikipedia by expanding it.